Welcome, Guest. Please login or register.
June 18, 2024, 12:12:56 pm

Login with username, password and session length

  • Total Members: 6309
  • Latest: Vicki
  • Total Posts: 55127
  • Total Topics: 4851
  • Online Today: 213
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 132
Total: 132


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Reasons to Treat Opioid Use Disorder and Hep C Together Abound  (Read 7355 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
For people with opioid use disorder (OUD) and hepatitis C virus (HCV), treating the two conditions at the same time is associated with manifold benefits, Healio reports.

Elana Rosenthal, MD, an assistant professor at the University of Maryland School of Medicine Institute of Human Virology, and colleagues conducted a prospective, open-label observational study called ANCHOR that included 100 people with OUD and HCV who engaged in ongoing injection drug use.

The participants, who were recruited for the study at a harm reduction drop-in center in Washington, DC, were offered buprenorphine, a form of medication-assisted treatment (MAT) to treat OUD, as well as 12 weeks of Epclusa (sofosbuvir/velpatasvir) for HCV.

For more...


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.